Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals-Reference-Cited by-同舟云学术

Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals

Published:2018-01 Issue: Volume:115 Page:49-55
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Tournoy Kurt G.,Thomeer Michiel,Germonpré Paul,Derijcke Sofie,De Pauw Rebecca,Galdermans Daniëlla,Govaert Karl,Govaerts Elke,Schildermans Rob,Declercq Isabelle,De Brucker Nele,Pat Karin,Van Herreweghe Rika,Van Zandweghe Luc,Vanmaele Luc,Van Damme Valerie,Marien Heidi,De Craene Sofie,Fabry Isabelle,Alexander Patrick,Vercauter Piet,Demedts Ingel

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference14 articles.

1. Immune checkpoint inhibitors for patients with advanced non-small-cell lung cancer: a systematic review;Ellis;Clin. Lung Cancer,2017

2. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

3. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

4. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis treatment and follow-up;Novello;Ann. Oncol.,2016

5. Systemic therapy for stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update;Hanna;J. Clin. Oncol.,2017

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‑world evidence of advanced non‑small cell lung carcinoma treated with an immune checkpoint inhibitor plus chemotherapy;Oncology Letters;2024-06-27

2. Exploring the value of routinely collected data on EQ-5D-5L and other electronic patient-reported outcome measures as prognostic factors in adults with advanced non-small cell lung cancer receiving immunotherapy;BMJ Oncology;2024-05

3. Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on KRAS G12C;Lung Cancer;2023-10

4. Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice;Journal of Clinical Medicine;2023-03-21

5. Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts;Cancers;2022-12-13